Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25380452 | 0.88 | MAPT (0.38) | MAPTTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL149834 | 0.88 | MAPT (0.38) | MAPTTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL2984199 | 0.88 | MAPT (0.38) | MAPTTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL25382868 | 0.88 | MAPT (0.38) | MAPTTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL2980293 | 0.88 | MAPT (0.38) | MAPTTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL10663433 | 0.83 | FAAH (0.35) | TSHRCHRM1 | |
| SCHEMBL3815702 | 0.83 | TSHR (0.38) | TSHR | |
| SCHEMBL5724019 | 0.82 | CTSK (0.33) | — | |
| SCHEMBL1217615 | 0.81 | TSHR (0.42) | MAPTTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL31731025 | 0.81 | MAPT (0.35) | MAPTTSHRCHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677331-B2 | HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
| US-6458780-B1 | IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1101766-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-5405844-A | Tetracyclic antibiotics and processes for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-11 | — | — | US | disclosed |
| EP-0517065-A1 | Tetracyclic beta-lactam antibiotics and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | MAPT 4427/4885TSHR 4209/4885CHRM2 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.